Clinical trial
A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
NCT00404521 · PharmaMar, Industry · Terminated
Key facts
| NCT number | NCT00404521 |
|---|---|
| Title | A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors |
| Official title | A Phase I Single-institution, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors. |
| Lead sponsor | PharmaMar, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | PM02734 |
| Enrollment | 56 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Nov 28, 2006 |
| Last update posted | Mar 26, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: